Okayama University Introduces Groundbreaking PSMA Lutetium Therapy for Advanced Prostate Cancer

Introduction of PSMA Lutetium Therapy at Okayama University

On February 24, 2026, Okayama University announced the introduction of a cutting-edge treatment for metastatic castration-resistant prostate cancer. This new therapy, known as PSMA Lutetium therapy, is aimed at patients whose existing treatments, such as hormone therapy and chemotherapy, have proven ineffective.

Key Highlights of the New Treatment

The treatment employs a radioactive ligand that specifically targets prostate cancer cells. By utilizing a substance that binds to the PSMA (prostate-specific membrane antigen) markers prevalent on the surface of these cancer cells, this therapy delivers radiation directly to the cancerous cells. This innovative approach allows for high efficacy in treating patients with previously limited options, significantly extending their survival and maintaining their quality of life.

A Vital Step for Patients

As a pivotal hospital in the Chugoku and Shikoku regions of Japan, Okayama University Hospital aims to provide new therapeutic options for patients facing an alarming prognosis. The introduction of PSMA Lutetium therapy signifies a major milestone in the fight against prostate cancer. Professor Motoharu Araki, head of the department of Urology, expressed his enthusiasm for this advancement, stating that it offers renewed hope for patients who might feel despondent due to lack of treatment options.

Collaborative Efforts for Effective Treatment

The initiative involves collaborative efforts among various departments, including Urology, Radiology, and nursing, to ensure the delivery of safe and precise treatment. Research Associate Tatsuya Kawada emphasized the importance of this cooperative approach, describing the therapy as a means to "directly strike the enemy" through exact targeting, thus minimizing unnecessary radiation exposure to healthy tissues.

Conclusion

The addition of PSMA Lutetium therapy at Okayama University Hospital marks a significant advancement in the treatment landscape for prostate cancer, particularly for those impacted by this aggressive form of the disease. With ongoing commitment to innovation and patient care, Okayama University is poised to lead the way in establishing groundbreaking cancer therapies, providing hope and improved outcomes for patients across Japan.

For more information, please visit the official Okayama University Hospital website: Okayama University Hospital.